Leslie's Announces Seasoned Retail Executive Amy College as Chief Merchandising and Supply Chain Officer
Ms. College has more than 25 years of retail operations leadership experience including merchandising, supply chain and store operations. Ms. College spent nearly five years at Petco (NASDAQ: WOOF) and most recently served as Chief Merchandising and Supply Chain Officer where she was responsible for category merchandising, enterprise demand planning, visual merchandising, owned brand product development and sourcing as well as distribution operations. Previously, Ms. College served as Senior Vice President, Operations, Strategy and Territory General Manager for Petco stores. Prior to joining Petco, Ms. College spent more than 20 years at Best Buy. During her tenure, Ms. College served in merchandising and category management leadership roles, including Chief Category Officer for the company's home theater, smart home, digital imaging and appliances. She holds a bachelor's degree in business from the University of Minnesota's Carlson School of Management.
'We are thrilled to welcome Amy to our leadership team at this pivotal time in Leslie's transformation,' said Jason McDonell, Leslie's chief executive officer. 'With significant retail, merchandising and general management experience, she brings a unique blend of strategic vision and operational expertise that I am confident will help guide us through this next chapter and deliver against our transformation initiatives. I am confident her values-driven leadership style and deep commitment to customer experience will be instrumental in accelerating our progress, strengthening cross-functional collaboration and delivering results that position us for long-term success.'
About Leslie's
Founded in 1963, Leslie's is the largest and most trusted direct-to-customer brand in the U.S. pool and spa care industry serving residential customers and pool professionals nationwide. The company serves the aftermarket needs of residential and professional consumers with an extensive and largely exclusive assortment of essential pool and spa care products. The company operates an integrated ecosystem of over 1,000 physical locations and a robust digital platform, enabling consumers to engage with Leslie's whenever, wherever, and however they prefer to shop. Its dedicated team of associates, pool and spa care experts, and experienced service technicians are passionate about empowering Leslie's consumers with the knowledge, products, and solutions necessary to confidently maintain and enjoy their pools and spas.
Contact
Elisabeth Eisleben
Senior Vice President, Investor & Public Relations
Leslie's, Inc.
investorrelations@lesl.com
Forward-Looking Statements
This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this press release, including statements regarding our future results of operations or financial condition, business strategy, value proposition, legal proceedings, competitive advantages, market size, growth opportunities, industry expectations, and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would,' or the negative of these words or other similar terms or expressions. Our actual results or outcomes could differ materially from those indicated in these forward-looking statements.
You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this press release primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, and operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, and other factors described in Part I, Item 1A, 'Risk Factors' in our Annual Report on Form 10-K for the year ended September 28, 2024 and in our other filings with the SEC. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time-to-time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results or outcomes could differ materially from those described in the forward-looking statements.
In addition, statements that 'we believe' and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this press release, and while we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
16 minutes ago
- Globe and Mail
Why TMC The Metals Company Skyrocketed Last Week
Key Points TMC The Metals Company stock surged 16.5% and is now up more than 580% year to date. The stock's big gains are being driven by expectations that the company will receive approval to begin its seabed mining operations. Adversarial relations between the U.S. and China have created a backdrop that has made TMC's seabed mining capabilities more valuable. 10 stocks we like better than TMC The Metals Company › TMC The Metals Company (NASDAQ: TMC) stock posted strong gains over the past week of trading. The seabed mining specialist's share price rose 16.3% over the stretch. Meanwhile, the S&P 500 index climbed 0.6%. While there wasn't any major news for the company in the week, TMC stock continued to see strong bullish momentum thanks to the possibility that the company will score a major regulatory approval in the not-too-distant future. Its share price has skyrocketed 158% over the past three months and 582% year to date. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Investors stay bullish on TMC's seabed mining bet In light of tense relations between the U.S. and China, access to rare earth minerals has become a key strategic priority for the Trump administration. The dynamic has helped to power huge gains for TMC stock, and its share price booked another week of big gains this week despite no fresh bullish news developments. In April, President Trump signed an executive order to accelerate the the review process for mining applications. TMC quickly submitted its first application for seabed mining approval, and investors have been betting that the company could soon be given the go-ahead to commence operations. Could recent Nvidia news derail TMC's rally? Despite posting strong gains in this week's trading, there may have actually been a significant bearish development for the mining specialist. After a meeting between Nvidia CEO Jensen Huang and President Trump, the artificial intelligence (AI) hardware leader announced that it was on track to receive export licenses to sell its H20 processors in China. The sale of the processors into the Chinese market was effectively banned by the Trump administration earlier this year, but it looks like the export licenses are now being granted as part of ongoing trade negotiations. U.S. government officials have said that the shift on the export license stance is connected to negotiations to secure access to Chinese rare earth minerals. While a deal on rare earth minerals could cause substantial volatility for TMC stock, it's also likely that the U.S. will still continue making moves to bolster its domestic mineral sourcing capabilities. Should you invest $1,000 in TMC The Metals Company right now? Before you buy stock in TMC The Metals Company, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and TMC The Metals Company wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
Globe and Mail
2 hours ago
- Globe and Mail
Why BigBear.ai Stock Skyrocketed Last Week
Key Points stock surged 23.5% over the past week despite no major news for the business. The company's share price has continued to climb thanks to excitement surrounding defense-AI investments. explosive valuation has seen explosive gains lately despite little indication the company's outlook has seen big shifts. 10 stocks we like better than › (NYSE: BBAI) stock closed out this past week's trading with another run of big gains. The software and services company's share price climbed 23.5% from the previous week's market close amid a gain of 0.6% for the S&P 500 index. valuation surged again this past week, as investors continued to place bullish bets on companies with artificial intelligence (AI) tools tailored for the defense industry. The company's share price is now up 101% over the past month and 214% over the past three months. stock continues to surge despite no major news Even in the absence of apparent meaningful developments for the business, stock has continued to rally. The company's big valuation gains appear to be primarily connected to the defense-AI investment trend that has been hot in the market. Palantir has been a top defense-AI play and reached a new valuation high in this week's trading, and stock has often seen valuation moves that correspond with pricing action for the software leader. Some investors are betting that could emerge as a Palantir-like winner as demand for AI-powered defense software continues to increase. What's next for The massive valuation run up for stock appears to be out of step with the company's recent business performance and near-term outlook. Despite demand tailwinds in the AI industry, the company's revenue increased just 5% year over year in the last quarter. Growth is expected to accelerate in the second half of the company's current fiscal year, but management's midpoint target for annual sales growth of roughly 7.5% still raises valuation concerns following recent gains for the stock. While it's possible that continued acceleration for sales growth and margin improvements will pave the way for stock to see more explosive gains above its current valuation level, huge valuation gains in the absence of major news suggest that the company is a risky investment right now. Investors will get a closer look at the business on Aug. 11, when the company publishes its next quarterly report. Should you invest $1,000 in right now? Before you buy stock in consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
Globe and Mail
3 hours ago
- Globe and Mail
3 Monster Stocks in the Making to Buy Right Now
Key Points CRISPR Therapeutics is still in its early growth stage. Summit Therapeutics has plenty of upside potential remaining. Viking Therapeutics is targeting two monster markets. 10 stocks we like better than CRISPR Therapeutics › Where can you find the next monster stocks? Check out the biotech space. It's not easy, but investors can sometimes find highly promising biotech stocks that are only in their early innings. Three Motley Fool contributors think they've identified monster stocks in the making. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX). Image source: Getty Images. A promising company in its early growth stage David Jagielski (CRISPR Therapeutics): Biotech company CRISPR Therapeutics has a market cap of around $5 billion, but it has the potential to be much more valuable in the long run. The gene editing market is still fairly small, but it has a lot of room to grow. Analysts from Grand View Research project that it will expand at a compound annual growth rate of more than 16% between now and 2030, when it will be worth $25 billion. As a leading company in the space, CRISPR Therapeutics is well positioned to benefit from future growth in this area of healthcare. The company, and its key development partner, Vertex Pharmaceuticals (NASDAQ: VRTX), already have an approved gene therapy treatment in Casgevy, which regulators have approved for both sickle cell disease and transfusion-dependent beta-thalassemia. The companies will share in the profits on the treatment (CRISPR will take 40%). Casgevy is still in its early growth stages. CRISPR is also working on developing treatments for type 1 diabetes and cardiovascular disease. While CRISPR remains unprofitable today, its future does look bright. It's a long road ahead for CRISPR Therapeutics, but with an encouraging pipeline and a lot of growth potential, this could be a monster healthcare stock in the making. The business is well funded with its cash and marketable securities as of the end of March totaling nearly $1.9 billion, putting it in an excellent position to continue investing in its research and development efforts. CRISPR can make for an excellent investment, but it's also one you'll need to be patient with. Still plenty of upside left for this stock Prosper Junior Bakiny (Summit Therapeutics): Few biotech companies have performed better than Summit Therapeutics over the past three years. The company's shares have soared by more than 2,000%, making early investors who held on significantly wealthier in the process. Here's the good news for those who are still considering the stock: There could be a massive upside left for Summit Therapeutics. Though the biotech generates no revenue and is unprofitable, it has one of the more promising pipeline products in the industry. Summit Therapeutics' leading candidate is a cancer medicine called ivonescimab, which it licensed out from Akeso Biopharma (OTC: AKES.F), a China-based drug developer. The medicine has been extensively tested in China, where it has already received approval in certain indications. One of ivonescimab's most promising markets is non-small cell lung cancer (NSCLC). In a phase 3 study in China, it went head-to-head against the market leader and the world's best-selling drug: Merck 's (NYSE: MRK) Keytruda. Ivonescimab emerged victorious, leading to a greater decrease in the risk of recurrence or death among NSCLC patients with a PD-L1 protein overexpression. Summit Therapeutics is conducting clinical studies to support approval in the U.S. and other regions. Furthermore, the biotech is likely to seek a series of approvals and label expansions over the years, based on the number of clinical trials and indications Akeso is targeting in China. Ivonescimab should easily become a blockbuster and generate strong sales for years. That's why it's not too late to invest in Summit Therapeutics. If ivonescimab achieves its full potential, Summit could deliver market-beating returns in the next five to 10 years and establish itself as a prominent player in the biotech industry. Targeting two monster markets Keith Speights (Viking Therapeutics): The big story for Viking Therapeutics is its experimental obesity drug VK2735. The company recently advanced a subcutaneous formulation of this candidate into late-stage clinical testing after announcing highly encouraging results from a phase 2 study last year. Viking is also evaluating an oral version of VK2735 in a separate phase 2 clinical trial, and it expects to report results from that study later in 2025. In addition, the drugmaker plans to initiate a clinical study for a monthly maintenance version of subcutaneous VK2735 in the coming months. Morgan Stanley Research projects that the global obesity drug market could reach $150 billion by 2035. Viking could be in a great position to claim a nice chunk of that market if VK2735 fulfills its potential. Obesity isn't the only big market that the company is targeting, though. In 2023, Viking reported positive results from a phase 2 study of VK2809 in treating metabolic-associated steatohepatitis (MASH), a chronic liver disease also known as nonalcoholic steatohepatitis (NASH). The company is seeking a partner to advance VK2809 into late-stage testing, so it can dedicate its financial resources exclusively to VK2735 for now. Grand View Research predicts the MASH/NASH market could hit $33.8 billion by 2030, so that's a nice opportunity. A clinical trial flop for VK2735 and/or a failure to find a partner for VK2809 could prevent Viking from becoming a monster stock. However, I think the company's chances look pretty good. I also wouldn't be surprised if a larger drugmaker swoops in to acquire Viking. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
